Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $34.91 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest following dividend re-investment.
- Dividend Date: July 8, 2010.
Material Changes
The filing reports specific increases in shareholdings for two individuals:
- Mrs C E Bruck Slaoui: 4.13 ADRs.
- Mr D J Phelan: 243.85 ADRs.
No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding insider trading rules (Disclosure and Transparency Rule 3.1.4R(1)(a)).
Investor Verification Checklist
- Verify the total number of ADRs held by Mrs C E Bruck Slaoui and Mr D J Phelan post-transaction.
- Confirm the dividend amount per share paid on July 8, 2010, to validate the re-investment calculation.
- Review the full GlaxoSmithKline Performance Share Plan rules to understand the mechanics of the dividend re-investment.